Table 2. All Reports Included in This Review and Additional Information.

References	Description of study	Medications	Dosages	Effects
Bertino et al (1991) [17]	Randomized controlled double-blind study, involving 18 male college students. The objective was to test reduction in intake of food with administration of naltrexone	Naltrexone	50 mg administered once daily in tablet form	Reduction in intake of food after administration of naltrexone
Billes (2014) [25]	Systematic review of literature assessing effectiveness of combining naltrexone and bupropion in promoting weight loss	Naltrexone and bupropion	8 mg of naltrexone + 90 mg of bupropion	Profound and sustained reduction in weight loss
Drewnowski et al (1995) [23]	Randomized controlled double-blind study assessing effects of naloxone on food consumption	Naloxone	6 mg bolus followed by a 0.1 mg per kg every hour, administered intravenously for 2.5 h	Reduction in binge eating habits but no significant effect on weight loss
Holtzman (1979) [24]	Randomized controlled trial involving rats. The objective was to determine effect of naloxone in suppressing eating and drinking habits	Naloxone	0.3 - 10 mg/kg administered intravenously	Suppression of eating and drinking in a dose-related manner
Kumar and Aronne (2017) [29]	Book section discussing pharmacotherapy for obesity	Combination of naltrexone and bupropion	Naltrexone 32 mg and bupropion 360 mg	Significant weight loss when combined with lifestyle modification
Lee and Fujioka (2009) [27]	Extensive systematic review of literature to assess use of naltrexone in treatment of obesity	Naltrexone	50 mg tablet	Monotherapy is associated with insignificant loss of weight
Malcolm et al (1985) [28]	Randomized controlled trial assessing effectiveness of naltrexone in obesity reduction. The trial was carried out for 10 weeks and involved 14 subjects who were male and 27 subjects who were female. A placebo was used for the control group	Naltrexone	Daily dosage of 200 mg	No significant reduction in body weight
Mason et al (2015) [37]	Randomized controlled trial	Naltrexone	25 mg on day 1 followed by 50 mg daily for 2 days	Reduction in reward-driven eating and craving for food
Moore et al (1981) [21]	Randomized controlled trial. They sampled 12 female patients who were suffering from anorexia nervosa who were in the inpatient unit of a hospital. These subjects were between the age of 16 years and 38 years, with 37.6 kg as their mean weight. They were subjected to a regimen characterized with punishment and reward, with the inclusion of amitriptyline for treating depression after being admitted at the hospital for a period not less than 2.9 weeks; the subjects were given naloxone through intravenous infusion. Administration of naloxone was continued for 5 weeks, on average. Two of these participants were given normal saline intravenously as a placebo one week prior and a week after infusion with naloxone. Per study protocol, their blood was tested	Naloxone	Initial dose ranged between 1.0 mg every 12 h and 3.2 mg, increased after week 1 to between 3.2 mg and 6.4 mg	Naloxone had antilipolytic effect that was responsible for weight gaining
Rebello and Greenway (2016) [36]	Systematic literature review	Naltrexone and bupropion combination	32 mg/360 mg	Reduction in frequency and strength of cravings for food
Selleck and Baldo (2017) [30]	Systematic literature review: prefrontal cortex-based opioid effects were compared to those elicited from the NAcc, to glean possible common functional principles; the motivational effects of opiates were discussed			Eating was induced by action of opioids in prefrontal cortex and NAcc through enhancement of reactivity to taste
Sinclair (2006) [19]	Patent on use of naloxone to treat eating disorders	Naloxone		Reduction in bulimia
Stolar (1988) [20]	Chapter overview on effects of naloxone on eating disorders like hyperphagia	Naloxone		Reduction of severity of hyperphagia
Yeomans and Gray (1996) [31]	A randomized placebo-controlled double-blind study to determine effects that naltrexone has on intake of food and its pleasantness	Naltrexone	50 mg of naltrexone	The amount of food intake reduced but sweetness and saltiness of food was not affected by naltrexone
Giuliano et al (2012) [26]	In-lab study on rats	GSK1521498 Naltrexone	GSK1521498 (0.1, 1 and 3 mg/kg) or naltrexone (NTX, 0.1, 1 and 3 mg/kg)	Both compounds reduced binge-like palatable food hyperphagia. Reduced food-seeking behavior
Yanovski and Yanovski (2015) [32]	Review article	Naltrexone-extended release plus bupropion -extended release (NB) (brand name, Contrave)	This preparation consists of a combination of 360 mg of bupropion and 32 mg of naltrexone	Preparation is effective and FDA-approved for adults with BMI ≥ 30 kg/m2 or with BMI ≥ 27 kg/m2 plus obesity-related comorbidities